Table 2.

Characteristics of Daptomycin comparative SSTI studies

Study	Design	Patient characteristics	Daptomycin (dose, treatment duration)	Comparator (type, dose, treatment duration)
Arbeit15	2 multicenter evaluator-blinded RCTs	N = 1092, adults with Gram-positive cSSTIs requiring hospitalization and IV antibiotics for ≥4 days	4 mg/kg IV once daily for 7–14 days	Vancomycin IV 1 g bd for 7–14 days or penicillinase-resistant penicillin IV 4–12 g IV q.d in equally divided doses
Davis36	Prospective open label	N = 56, hospitalized adults, cSSTIs at risk of MRSA, prospectively enroled; 212 historical controls treated with vancomycin	4 mg/kg IV once daily for 3–14 days	Vancomycin IV dosed according to trough concentrations ≥3 days switched to semi-synthetic penicillin in absence of MRSA infection
Katz35	Multicenter, semi-single blinded RCT	N = 100, adults with cSSTIs at risk of MRSA, requiring IV antibiotics	10 mg/kg IV once daily for 4 days	Vancomycin IV 1 g bd or semi-synthetic penicillin IV 2 g q4h for ≤14 days
Pertel34	Multicenter, evaluator-blinded RCT	N = 103, adults with SSTI requiring hospitalization/iv antibiotics	4 mg/kg IV once daily for ≤14 days	Vancomycin IV standard doses for 7–14 days
Gollnick33	Phase IIIb multicenter RCT	N = 189, adults with cSSTI requiring hospitalization	4 mg/kg once daily for 4–14 days	IV Vancomycin or Teicoplanin for 4–14 days

Abbreviations: CE, clinically evaluable; ITT, intent-to-treat (all patients who received one or more doses of study medication); RCT, randomized controlled trial; IV, intravenous; cSSTI, complicated skin and soft tissue infections.